Amarin | AMRN - L'Utile Operativo





L'Utile Operativo Cambiamento Data
AbbVie USD 6.88B 156M 2026-09
Alnylam Pharmaceuticals USD 179.66M 67.06M 2026-09
Amarin USD -2.26M 564K 2025-12
AstraZeneca USD 4.66B 1.5B 2026-09
BioCryst Pharmaceuticals USD 98.46M 161.92M 2026-06
DBV Technologies USD -64.8M 16.9M 2026-09
GlaxoSmithKline GBP 2.86B 251M 2026-09
Halozyme Therapeutics USD -60.68M 3.04M 2026-09
Heron Therapeutics USD 38K 3.83M 2025-12
Ionis Pharmaceuticals USD -130M 27.71M 2026-09
Nektar Therapeutics USD -38.26M 19.17M 2026-03
Neurocrine Biosciences USD 343M 123.1M 2026-09
Novartis USD 5.14B 392M 2026-09